As per the research report, the Asia-Pacific Platelet Rich Plasma market size was around USD 62.59 million in 2019. It is expected to grow at a CAGR of 15.92% to reach USD 131.01 million by 2024 during the forecast period 2019-2024.
Platelet-rich Plasma is purified plasma protein with red blood cells removed out of it and used for its greater concentration of growth factors. Platelet-rich plasma can regenerate ligaments and tendon fibres. PRP treatments are tissue healing techniques with a wide range of applications. Rise in Cosmetic surgeries and orthopaedic diseases are the key growth factors of this market. In some cases, PRP therapy can prevent the need for surgery which is helping the market grow rapidly. The lack of any possible side effects of this process is making the demand for PRP much higher.
This research report segmented and sub-segmented into the following categories:
The market is dominated by pure PRP segment because of less inflammatory responses and effective results in bone regeneration. Leukocyte-rich PRP is expected to rise with a high growth rate owing to its efficiency in healing soft tissue. PRP therapy is the go-to method for soft tissue healing and thus is projected to grow steadily in market value in upcoming years.
With growing awareness towards PRP therapy, there is huge potential for Platelet Rich Plasma market to thrive in Asia-Pacific region over the next decade.
The Top companies leading in the APAC Platelet Rich Plasma Market profiled in the report are DR. PRP AMERICA, LLC, Glofinn Oy, Zimmer Biomet, DePuy Synthes, Emcyte Corporation,Terumo BCT, Anthrex Inc, T-Biotechnology, Stryker.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Orthopedics
5.1.3 Cosmetic Surgery
5.1.4 Ophthalmic surgery
5.1.5 Neurosurgery
5.1.6 Y-o-Y Growth Analysis, By Application
5.1.7 Market Attractiveness Analysis, By Application
5.1.8 Market Share Analysis, By Application
5.2 Product
5.2.1 Introduction
5.2.2 Pure
5.2.3 Leukocyte-Rich
5.2.4 Leukocyte-Rich Fibrin
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Origin
5.3.1 Introduction
5.3.2 Homologous PRP
5.3.3 Autologous PRP
5.3.4 Allogeneic PRP
5.3.5 Y-o-Y Growth Analysis, By Origin
5.3.6 Market Attractiveness Analysis, By Origin
5.3.7 Market Share Analysis, By Origin
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product
6.1.3.4 By Origin
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Product
6.1.4.4 By Origin
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Product
6.1.5.4 By Origin
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Zimmer Biomet
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 DR. PRP AMERICA
8.3 LLC
8.4 Gloffin Oy
8.5 Depuy Synthes
8.6 Emcyte Cororation
8.7 Terumbo BCT
8.8 Anthrex Inc
8.9 T-Biotechnology
8.10 Stryker
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
